Emberi bánásmód veszteségek idején

Humane Treatment of People Who Experience Losses. In this paper, we present the grief as a natural response to the losses that people experience. We regard grief as an adaptive mechanism to the new situation that occurs with a loss. In our success-oriented consumerist society, grief has become a taboo: fighting pain in losses became a sign of weakness and failure. This is valid also for Christians, who consider faith as the measure of successful dealing with distress. We present the positive perceptive structures that may help the grief – based on Anil Seth’s theories. Later on, we speak about the toxic positivism, which harms the grieving person and the adequate expression of condolence, which may express our participation in his/her tormented situation. Destructive attitude consists in shaming, abandoning, or betraying the grieving person, whereas constructive attitude means acceptance, condolence, and support. This paper tries to provide a practical guideline to an empathic grief counselling. Keywords: grief, loss, mourning, toxic positivism, positive perceptive structures

A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis

SummaryGenomics-driven drug discovery is indispensable for accelerating the development of novel therapeutic targets. However, the drug discovery framework based on evidence from genome-wide association studies (GWAS) has not been established, especially for cross-population GWAS meta-analysis. Here, we introduce a practical guideline for genomics-driven drug discovery for cross-population meta-analysis, as lessons from the Global Biobank Meta-analysis Initiative (GBMI). Our drug discovery framework encompassed three methodologies and was applied to the 13 common diseases targeted by GBMI (Nmean = 1,329,242). First, we evaluated the overlap enrichment between disease risk genes and the drug-target genes of the disease-relevant medication categories. An omnibus approach integrating the four gene prioritization tools yielded twice the enrichment in the disease-relevant medication categories compared with any single tool, and identified drugs with approved indications for asthma, gout, and venous thromboembolism. Second, we performed an endophenotype Mendelian randomization analysis using protein quantitative trait loci as instrumental variables. After the application of quality controls, including a colocalization analysis, significant causal relationships were estimated for 18 protein–disease pairs, including MAP2K inhibitors for heart failure. Third, we conducted an in silico screening for negative correlations between genetically determined disease case–control gene expression profiles and compound-regulated ones. Significant negative correlations were observed for 31 compound–disease pairs, including a histone deacetylase inhibitor for asthma. Integration of the three methodologies provided a comprehensive catalog of candidate drugs for repositioning, nominating promising drug candidates targeting the genes involved in the coagulation process for venous thromboembolism. Our study highlighted key factors for successful genomics-driven drug discovery using cross-population meta-analysis.